Biologics for psoriasis: current evidence and future use

@article{Griffiths2012BiologicsFP,
  title={Biologics for psoriasis: current evidence and future use},
  author={C. Griffiths},
  journal={British Journal of Dermatology},
  year={2012},
  volume={167}
}
  • C. Griffiths
  • Published 2012
  • Medicine
  • British Journal of Dermatology
Psoriasis is a chronic immune-mediated inflammatory disease which, in its severe form, is associated with significant comorbidities and increased mortality. Effective, long-term treatment of plaque psoriasis is challenging. Dermatologists are faced with an array of treatment options, and there is a wide variability in both initial response to treatment, response over time and side-effects. Consequently, dermatologists must continually adapt and ⁄or change therapies as required, on a patient-by… Expand

Topics from this paper

Leczenie biologiczne łuszczycy w Polsce
Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response – results of a phase II regimen‐finding trial

References

SHOWING 1-10 OF 12 REFERENCES
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
  • C.H. Smith, A. Anstey, +10 authors A.D. Ormerod
  • Medicine
  • The British journal of dermatology
  • 2009
...
1
2
...